- Previous Close
260.27 - Open
259.87 - Bid 239.39 x 200
- Ask 279.16 x 100
- Day's Range
255.76 - 261.60 - 52 Week Range
160.19 - 289.46 - Volume
536,843 - Avg. Volume
726,189 - Market Cap (intraday)
18.171B - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
44.84 - EPS (TTM)
5.77 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
314.06
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
www.insulet.comRecent News: PODD
View MorePerformance Overview: PODD
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PODD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PODD
View MoreValuation Measures
Market Cap
18.17B
Enterprise Value
18.61B
Trailing P/E
44.77
Forward P/E
62.11
PEG Ratio (5yr expected)
6.57
Price/Sales (ttm)
9.23
Price/Book (mrq)
15.00
Enterprise Value/Revenue
8.98
Enterprise Value/EBITDA
43.92
Financial Highlights
Profitability and Income Statement
Profit Margin
20.19%
Return on Assets (ttm)
6.80%
Return on Equity (ttm)
43.03%
Revenue (ttm)
2.07B
Net Income Avi to Common (ttm)
418.3M
Diluted EPS (ttm)
5.77
Balance Sheet and Cash Flow
Total Cash (mrq)
953.4M
Total Debt/Equity (mrq)
118.37%
Levered Free Cash Flow (ttm)
155.28M